Chlamydia W2
Description
The E.coli derived recombinant 6x His fusion at C-terminus protein contains Chlamydia Trachomatis MOMP protein epitopes, 66-165 amino acids.
Product Specs
Chlamydia W2 was purified by proprietary chromatographic technique.
Product Science Overview
The term “Chlamydia trachomatis W2 recombinant” refers to a genetically engineered version of the bacterium. Recombinant DNA technology involves combining DNA from different sources to create new genetic combinations that are of value in research, medicine, agriculture, and industry. In the context of Chlamydia trachomatis, recombinant strains are often developed for vaccine research and development.
Recombinant strains of Chlamydia trachomatis, such as the W2 recombinant, are crucial in the development of vaccines. Traditional methods of controlling chlamydial infections, such as antibiotics, do not address the established pathology and often fail to prevent reinfection. Therefore, there is a significant need for effective vaccines .
Research has identified several antigens from Chlamydia trachomatis that elicit immune responses. These antigens are used to develop subunit vaccines, which include only the parts of the pathogen that stimulate the immune system. The W2 recombinant strain is one of the candidates being studied for its potential to induce protective immunity against Chlamydia trachomatis infections .
Current research focuses on identifying the most effective antigens and adjuvants (substances that enhance the body’s immune response to an antigen) to include in the vaccine formulation. Studies have shown that certain antigens, when combined with specific adjuvants, can provide solid protection against Chlamydia trachomatis in animal models .
Future research aims to refine these vaccine candidates and conduct clinical trials to evaluate their safety and efficacy in humans. The ultimate goal is to develop a vaccine that can be widely used to prevent Chlamydia trachomatis infections and reduce the global burden of this disease .
